Form 4: SOPHIA GENETICS: Insider Sells Shares for Tax Withholding

Manuela Valente, Chief People Officer at SOPHiA GENETICS SA, sold 3,824 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

Summary

• Manuela Valente, Chief People Officer of SOPHiA GENETICS SA, sold 3,824 ordinary shares on April 8, 2026.
• The sale was conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units on April 2 and 3, 2026.
• These transactions were executed as part of a pre-established Rule 10b5-1 trading plan, indicating they were not discretionary.
• The shares were sold at a weighted average price of $4.849, with individual sales ranging from $4.78 to $4.94.
• Following the sale, Valente beneficially owns 215,451 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves an insider selling shares, the sale is explicitly for tax withholding under a pre-arranged plan, which mitigates concerns about negative sentiment towards the company's future performance.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, suggesting a pre-determined and non-discretionary strategy for managing share sales.
• The sale was specifically to cover tax obligations, a common and expected event for executives upon vesting of equity awards.
• The reporting person retains a significant number of shares (215,451) after the transaction.

Negatives

• A portion of the insider's holdings was sold, which could be perceived negatively by the market, despite the stated reason.
• The weighted average sale price of $4.849 indicates a potential decrease in value from previous holdings or expectations, though the range is provided.

Risks

• Potential for negative market perception of insider selling, even if for tax purposes.
• The weighted average sale price of $4.849 might be lower than anticipated by some investors, though the filing provides a range of sale prices.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on a past transaction.

Management Comments

• Sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding purposes under Rule 10b5-1 plans are a common and generally accepted practice in the biotechnology and healthcare technology sectors, where equity-based compensation is prevalent. This filing reflects standard executive financial planning rather than a negative view on the company's prospects.

Stakeholder Impact

• Shareholders: The sale is unlikely to have a significant negative impact due to its nature as a tax-related transaction under a Rule 10b5-1 plan. However, any insider selling can create minor downward pressure or perception issues.
• Employees: The transaction relates to executive compensation and vesting of RSUs, which is a standard component of employee incentive structures.
• Management: The transaction reflects standard financial management by the Chief People Officer.

Next Steps

• The reporting person will continue to hold 215,451 ordinary shares.
• The reporting person may provide further details on specific sale prices upon written request.

Key Dates

Keywords

SOPHiA GENETICS, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Compensation, Beneficial Ownership